← Back to Search

Geriatric Assessment + Fitness Trackers for Gastric Cancer

N/A
Recruiting
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

Summary

This trialaims to improve care for older metastatic gastric cancer patients by increasing awareness of unique needs & assessing feasibility of geriatric self-assessments.

Who is the study for?
This trial is for English-speaking adults aged 70 or older with metastatic gastric cancer (including mGE junction cancer), who are currently undergoing any form of active therapy such as chemotherapy, immunotherapy, or Her-2 targeted therapy. They should be able to give consent and complete self-assessments, with a life expectancy of at least three months.
What is being tested?
The study aims to improve care for older patients with metastatic gastric cancer by educating oncology providers on geriatric assessments' role in treatment guidance. It will explore the use of fitness trackers to evaluate functional status and incorporate geriatric self-assessments into clinical practice over four phases.
What are the potential side effects?
Since this trial focuses on educational sessions and assessments rather than new medications, side effects may not be directly related to interventions. However, participants might experience discomfort or fatigue from completing assessments or wearing fitness trackers.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of geriatric abnormalities detected. (Tool used: Comprehensive Geriatric Assessment)
Percentage of treatment plan changes. (Count # of treatment changes 2-3 months after comprehensive geriatric assessment. Site coordinators will complete follow-up chart review of each patient to see what, if any, changes were made)
Secondary study objectives
Fitbit assessed functional status. Fitbit data: calories burned
Fitbit assessed functional status. Fitbit data: distance logged
Fitbit assessed functional status. Fitbit data: floors climbed
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Provider Didactic InterventionExperimental Treatment2 Interventions
Phase 1 - Providers complete a needs assessment questionnaire, which evaluates the approach to older mGC patients at each site. Phase 2 - Providers participate in an hour-long didactic session and begin enrolling eligible metastatic gastric cancer (mGC) patients. Enrolled mGC patients complete a comprehensive geriatric assessment (CGA). Providers complete the treatment plan and review of geriatric assessment questionnaires, which also includes an evaluation of their overall view of the utility of the geriatric assessment. Phase 3 - Follow-up chart reviews (2-3 months post intervention) are completed to assess for actual implementation of recommended interventions identified by the geriatric assessment.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyIndustry Sponsor
2,640 Previous Clinical Trials
3,223,314 Total Patients Enrolled
Fox Chase Cancer CenterLead Sponsor
233 Previous Clinical Trials
38,811 Total Patients Enrolled
National Comprehensive Cancer NetworkNETWORK
118 Previous Clinical Trials
7,790 Total Patients Enrolled

Media Library

Didactic Session Clinical Trial Eligibility Overview. Trial Name: NCT04618809 — N/A
Gastric Cancer Research Study Groups: Provider Didactic Intervention
Gastric Cancer Clinical Trial 2023: Didactic Session Highlights & Side Effects. Trial Name: NCT04618809 — N/A
Didactic Session 2023 Treatment Timeline for Medical Study. Trial Name: NCT04618809 — N/A
~20 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top